The ethical case for placebo control in HIV-cure-related studies with ART interruption
Many studies that seek to cure HIV must ask participants to interrupt their antiretroviral treatment. In such circumstances, is it permissible to include a placebo group in the study? We explain why doing so is a scientific and an ethical necessity, and more benign than imagined.
Saved in:
Main Authors: | Monica Magalhaes (Author), Daniel R. Kuritzkes (Author), Nir Eyal (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
59 Interrupting HIV treatment in cure research: scientific and ethical considerations
by: S. Garner, et al.
Published: (2016) -
Progress toward HIV cure
by: Daniel Kuritzkes
Published: (2016) -
Recruitment and ethical considerations in HIV cure trials requiring treatment interruption
by: Michael P. Arnold, et al.
Published: (2015) -
Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations
by: Samual A. Garner, et al.
Published: (2017) -
Maximising the global health impact of future HIV cure-related interventions through advance planning
by: Regina Brown, et al.
Published: (2018)